These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20455656)

  • 1. Achieving reimbursement for regenerative medicine products in the USA.
    Ginty PJ; Singh PB; Smith D; Hourd P; Williams DJ
    Regen Med; 2010 May; 5(3):463-9. PubMed ID: 20455656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.
    Oye KA; Eichler HG; Hoos A; Mori Y; Mullin TM; Pearson M
    Clin Pharmacol Ther; 2016 Dec; 100(6):626-632. PubMed ID: 27618128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-label use reimbursement.
    Cohen J; Wilson A; Faden L
    Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satisfying the requirements of the Food and Drug Administration and Centers for Medicare and Medicare Services.
    Smith JJ; Henderson JA
    J Am Coll Radiol; 2008 Mar; 5(3):189-92. PubMed ID: 18312966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lag from FDA approval to published cost-utility evidence.
    Chambers JD; Thorat T; Pyo J; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.
    Chambers JD; May KE; Neumann PJ
    Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Federal regulations and reimbursement for PET.
    Keppler JS
    J Nucl Med Technol; 2001 Dec; 29(4):173-9; quiz 180-2. PubMed ID: 11756528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.
    Bubela T; McCabe C; Archibald P; Atkins H; Bradshaw SE; Kefalas P; Mujoomdar M; Packer C; Piret J; Raxworthy M; Soares M; Viswanathan S
    Regen Med; 2015; 10(7):897-911. PubMed ID: 26565607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare coverage: engaging on evidence.
    Jensen TS; Jacques LB
    Regen Med; 2011 Nov; 6(6 Suppl):99-101. PubMed ID: 21999269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare payment for new technologies. Can the process be improved despite conflicting goals? An ECRI technology management assessment.
    J Health Care Technol; 1986; 3(1):13-32. PubMed ID: 10300959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics.
    Mahalatchimy A; Faulkner A
    Regen Med; 2017 Sep; 12(6):611-622. PubMed ID: 28972450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
    Jarosławski S; Toumi M
    BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential legal barriers to increasing CMS/FDA collaboration: the law of trade secrets and related considerations.
    Wang SS; Smith JJ
    Food Drug Law J; 2003; 58(4):613-27. PubMed ID: 15027453
    [No Abstract]   [Full Text] [Related]  

  • 16. The challenges of product development and commercialization in a convergence technology world: focus on regenerative medicine.
    Tozer D
    Drug Discov Today; 2010 Aug; 15(15-16):587-9. PubMed ID: 20546921
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
    J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Include Payers in Your Product Development and Clinical Use Processes.
    Schaum KD
    Adv Wound Care (New Rochelle); 2020 Nov; 9(11):632-635. PubMed ID: 32311305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reimbursement and adoption of advanced therapies: the 5-C framework.
    Malik NN
    Regen Med; 2014; 9(5):573-8. PubMed ID: 25372076
    [No Abstract]   [Full Text] [Related]  

  • 20. Reimbursement dilemma regarding home health-care products and services.
    Curtiss FR
    Am J Hosp Pharm; 1984 Aug; 41(8):1548-57. PubMed ID: 6433706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.